EBOSY (Ebos Group) 10-Year Sharpe Ratio: N/A (As of Sep. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EBOSY Ebos Group Ltd EBOSY
83 GF Score
Price $26.03
GF Value $49.57
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Ebos Group 10-Year Sharpe Ratio?

The 10-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past ten years. As of today (2026-09-14), Ebos Group's 10-Year Sharpe Ratio is Not available.

Ebos Group  (OTCPK:EBOSY) 10-Year Sharpe Ratio Explanation

The 10-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past ten years. It is calculated as the annualized result of the average ten-year monthly excess returns divided by its standard deviation in the ten-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Ebos Group 10-Year Sharpe Ratio Related Terms

EBOSY vs MCK, COR, CAH: 10-Year Sharpe Ratio Comparison

For the Medical Distribution subindustry, Ebos Group's 10-Year Sharpe Ratio, along with its competitors' market caps and 10-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ebos Group 10-Year Sharpe Ratio vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Ebos Group's 10-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Ebos Group's 10-Year Sharpe Ratio falls into.


EBOSY
83GF Score
Ebos Group Ltd EBOSY
10-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ebos Group 10-Year Sharpe Ratio Calculation

The 10-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last ten years. A stock / portfolio's 10-Year Sharpe Ratio can be calculated by dividing the difference between the ten-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past ten years.

Is Ebos Group (EBOSY) Overvalued in 2026?

Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued. The current stock price of $26.03 is trading 47.5% below its estimated GF Value™ of $49.57. GuruFocus considers Ebos Group to be Significantly Undervalued.

Key valuation signals for EBOSY:

  • 10-Year Sharpe Ratio: N/A
  • GF Value™: $49.57 vs. price of $26.03 (47.5% below fair value)
  • GF Score™: 83/100 with 5 warning signs

No single metric tells the full story. See the EBOSY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ebos Group Business Description

Address 737 Bourke Street, Level 7, Docklands, Melbourne, VIC, AUS, 3008
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
83GF Score

Get the complete analysis for EBOSY

10-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.03
Price
$49.57
GF Value